June 17, 2022

Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549


We have read Item 4.01 of Skye Bioscience, Inc.’s Form 8-K dated June 17, 2022, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements made by the registrant contained in Item 4.01. 

Very truly yours,

/s/ Mayer Hoffman McCann P.C.

Irvine, California